CURRENT ISSUE Current Issue Cover
VOL 11 NO 2 • MAR 2020
IN THIS ISSUE

The American Cancer Society’s Facts & Figures: 2020 Edition

Pamela Hallquist Viale, RN, MS, CNS, ANP

Burnout, Workplace Factors, and Intent to Leave Among Hematology/Oncology Nurse Practitioners

Laura Bourdeanu,(1) NP, PhD, Qiuping (Pearl) Zhou,(2) PhD, RN, Michelle DeSamper,(3) Kaitlin Anne Pericak,(4) MA, and Arlene Pericak,(2) FNP-BC, DA

An Advanced Practice Provider Initiative for Delirium Management in the ICU

Sarah Rebal, MS, RN, ACNP-BC, Caroline Shirzadi, MS, RN, ACNP-BC, Jennifer Agatep, Ms, RN, AGACNP, Konstantina Matsoukas, MLIS, Kay See Tan, PhD, Kenneth Seier, MS, Yesne Alici, MD, Beatriz Korc-Grodzicki, MD, PhD, and Louis Voigt, MD

 
Section Seperator

TODAY'S NEWS

Continuous Coverage of COVID-19

The staff of The ASCO Post recognizes the steady f...

Disparities in Receipt of Chemotherapy A...

In patients with non–small cell lung cancer (NSCLC...

Ivosidenib in Patients With Advanced IDH...

In a phase I study reported in the Journal of Clin...

Maintaining Blood Donations During the C...

A major casualty of the coronavirus disease 2019 (...

Gynecologic Cancer Screening After a Nat...

Cervical cancer screening rates were significantly...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Cytokine Release Syndrome

CAR T-cell therapy is rapidly emerging as a promising treatment for many hematologic malignancies...

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights More Highlights
 
Section Seperator
Section Seperator
 
 
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.